Rapid Influenza Diagnostics Market Size & Share, by Test Type (Influenza A Test, Influenza B Test, Influenza A+B Test); End User (Hospitals, Diagnostic Centers, Research Laboratories, Office Based Settings, Nursing Home); Distribution Channel (Retail, Direct) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5310
  • Published Date: Oct 12, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Rapid Influenza Diagnostics Market size is estimated to reach USD 36 billion by the end of 2036, expanding around 9% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of rapid influenza diagnostic was over USD 10 billion. The growth of this market can be attributed to the growing prevalence of influenza all around the world. The increasing number of people globally found with weak immunity systems suffering from target ailments are expected to raise the industry growth in the forthcoming years. Human influenza viruses consisting of Type A and Type B influenza are the most significant viruses that cause disease risk in humans. These issues contribute to healthcare costs and also disrupt health-associated quality of life. As per a report by the World Health Organization, globally around 3 – 5 million people suffer from severe cases of influenza.

The increased R&D spending for the provision of technically advanced solutions to diagnose influenza is expected to lead to a higher rate of global adoption of these tests. The market revenue for these tests is expected to expand over the coming years due to the widespread use of rapid influenza diagnostic testing and a growing incidence of influenza.

Rapid Influenza Diagnostics Market
Get more information on this report: Request Free Sample PDF

Rapid Influenza Diagnostics Sector: Growth Drivers and Challenges

Growth Drivers

  • Escalating Technological Advancements – Rapid molecular testing is a new type of highly sensitive and specific molecular diagnostic test for influenza diagnosis that has emerged in recent years. The ability to identify respiratory viruses has been significantly improved through the use of RT-PCR and nucleic acid labeling detection tests. Furthermore, the fundamental goal of molecular influenza diagnostics is to identify specific known pathogens using NAT. NAT is superior to other existing diagnostic devices in several aspects. They do not impact the survival of the target bacteria and can provide results within a clinically relevant time frame. They are capable of identifying low numbers of all known influenza viruses in clinical samples.
  • Increasing Awareness about the Advantages of Early Diagnosis - Another factor driving the need for rapid diagnostic testing for influenza is the growing understanding of the importance of early identification of viral diseases in the global population. In an effort to reduce or even eliminate disease-related mortality, organizations are implementing initiatives to encourage early detection. Make it important the medical decisions regarding support and treatment are made easier due to early diagnosis, for both patients and medical staff. Receiving a proper diagnosis as soon as possible after recognizing the cognitive symptoms associated with the medical condition has many benefits.


  • Variability in Test Sensitivity and Specificity – The sensitivity and specificity of rapid influenza diagnostic tests can vary depending on the type of test and the virus strain being tested. This can lead to false-positive and false-negative results. This is expected to hamper the market expansion of the rapid influenza diagnostics market in the upcoming time period.
  • High Cost of Development and Commercialization is Set to Restrict Market Expansion in the Future Times.
  • Strict Regulatory Requirements are Expected to Hamper the Market Growth in the Forecast Time Period.

Rapid Influenza Diagnostics Market: Key Insights

Base Year


Forecast Year

2024 – 2036



Base Year Market Size

~USD 10 billion

Forecast Year Market Size

~USD 36 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Rapid Influenza Diagnostics Segmentation

End User (Hospitals, Diagnostic Centers, Research Laboratories, Office Based Settings, Nursing Home)

Based on end user, the diagnostic centers segment is anticipated to hold the largest market share of 25% by the end of 2036.  The expansion can be attributed to increased demand and growing public knowledge of the advantages diagnostic centers offer in terms of giving accurate diagnoses connected to influenza respiratory infection. The importance of diagnostic facilities in identifying diseases at their earliest stages and minimizing the chance of treatment failure cannot be overstated. The patient histories and procedures of these facilities are also helping researchers enhance influenza treatment options through advanced influenza vaccine. Building diagnostic facilities that are outfitted with the highly effective necessary tests, competent specialists, and medical workers that aid in the process of recognizing influenza in a patient that is exhibiting specific symptoms or indicators is a top priority for several nations.

Test Type (Influenza A Test, Influenza B Test, Influenza A+B Test)

In terms of test type, the influenza A+B type segment in the rapid influenza diagnostics market is estimated to hold the largest revenue share during the time period between 2024 – 2036. The growth of this market can be attributed to the advantages associated with the test including ease of use, and quick diagnosis.

Our in-depth analysis of the global market includes the following segments:


     Test Type

  • Influenza A Test
  • Influenza B Test
  • Influenza A+B Test



     End User

  • Hospitals
  •  Diagnostic Centers
  •  Research Laboratories
  •  Office Based Settings
  • Nursing Home

     Distribution Channel

  • Direct
  • Retail

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Rapid Influenza Diagnostic Industry - Regional Synopsis

North American Market Forecasts

The North America rapid influenza diagnostics market is estimated to account for the highest revenue share of 33% by the end of 2036. The United States dominated the North American fast influenza diagnostic market in 2021, and it is predicted that it will continue to grow quickly throughout the foreseeable future. This can be attributed to the existence of significant market participants, a rise in the number of influenza cases, respiratory infections, etc. The CDC estimates that between October 1, 2021, and April 16, 2022, there were between 4,700,000 and 7,900,000 flu cases reported in the United States. Additionally, this flu season caused between 2,800 and 8,200 fatalities in the United States. These data demonstrate the growing need for influenza testing in the region that effectively uses quick diagnostic assays for the illness.

APAC Market Statistics

The rapid influenza diagnostics market in the Asia Pacific region is estimated to grow substantially by the end of the forecast period. The growth of this market can be ascribed to the back of growing healthcare expenditure in the region as a result of growing urbanization. Besides, increasing awareness about rapid influenza diagnostics among the people living in this world is expected to raise the market expansion of the market in the region during the forecast period.  

Research Nester
Rapid Influenza Diagnostics Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Rapid Influenza Diagnostic Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Hologic, Inc.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Abbott Laboratories
    • BD
    • F. Hoffmann-La Roche Ltd
    • NeuroLogica Corp.
    • Quest Diagnostics Incorporated
    • DiaSorin SpA

In the News

  • For its quick influenza diagnostic testing device, ID NOW INFLUENZA A & B 2, Abbott got U.S. FDA approval in October 2018. The influenza A and B viruses may be quickly identified and differentiated molecularly with this assay. This product approval helped the business increase its market presence and diversify its offering of influenza diagnostic tests.
  • The acquisition of Luminex Corporation, a business involved in the development of diagnostic tools for infectious diseases, was announced by DiaSorin SpA in April 2021. The goal of this acquisition was to increase the diagnostic goods available in the United States, including those for the diagnosis of influenza. This tactical choice helped the business grow its clientele and strengthen its position in the market.

Author Credits:  Radhika Pawar

  • Report ID: 5310
  • Published Date: Oct 12, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of influenza and growing research and development are some of the major factors anticipated to drive the growth of the rapid influenza diagnostics market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2024-2036.

The major players in the market are of Abbott Laboratories, BD, F. Hoffmann-La Roche Ltd, NeuroLogica Corp., GENERAL ELECTRIC, Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.,, and others.

The diagnostic centers segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Rapid Influenza Diagnostics Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying